Clinical trials: Kidney Disorder
Transplantation Infection, Epstein-Barr Virus Infections
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1.
- Conditions
- Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections
- Trial name
- NCT01972035
- Testing
- Valacyclovir, Valganciclovir
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Minnesota
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Anemia
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
This single-arm study will assess the efficacy and safety of monthly administration of intravenous methoxy polyethylene glycol-epoetin beta (CERA/Mircera) for the maintenance of hemoglobin (Hb) levels in participants on dialysis…
- Trial name
- NCT00660023
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 10 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin.
- Trial name
- NCT00077610
- Testing
- Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 673 people
- Sponsor
- Hoffmann-La Roche
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02680574
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 503 sites in United States, Argentina and 28 more
- Volunteers
- 1,725 people
- Sponsor
- Akebia Therapeutics
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function
The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment.
- Trial name
- SPARKLE (NCT04119843)
- Testing
- Mangoral
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 87 people
- Sponsor
- Ascelia Pharma AB
Aspergillosis, Invasive Fungal Infections
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal…
- Trial name
- VITAL (NCT00634049)
- Testing
- isavuconazole
- Where
- 96 sites in United States, Argentina and 17 more
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Inc
Diabetic Kidney Disease
A Phase 2b Diabetic Kidney Disease Study
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
- Trial name
- NCT04170543
- Testing
- MEDI3506, Dapagliflozin
- Where
- 97 sites in United States, Argentina and 5 more
- Volunteers
- 609 people
- Sponsor
- AstraZeneca
Renal Impairment
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
- Trial name
- NCT00999336
- Testing
- Betrixaban
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2)
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
- Conditions
- Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases
- Trial name
- PHYOX2 (NCT03847909)
- Testing
- DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
- Where
- 28 sites in United States, Australia and 13 more
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Kidney Disease, Chronic
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta).
- Trial name
- NCT02263833
- Testing
- Mircera
- Where
- South Korea
- Volunteers
- 748 people
- Sponsor
- Hoffmann-La Roche
Diabetic Nephropathy
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
- Trial name
- NCT03436693
- Testing
- Canagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Tanabe Pharma Corporation
Coronary Heart Disease, Stroke
Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes
To investigate long-term effects on cardiovascular mortality/morbidity and renal failure in type 1 diabetes patients former randomized to intensive insulin treatment
- Conditions
- Coronary Heart Disease, Stroke, Renal Failure
- Trial name
- SDIS (NCT02138006)
- Testing
- Intensive insulin treatment, Standard insulin treatment
- Where
- Sweden
- Volunteers
- 102 people
- Sponsor
- Karolinska Institutet
Renal Insufficiency
PF-04634817 Renal Impairment Study
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment.
- Trial name
- NCT01791855
- Testing
- PF-04634817
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Disease, Cardiovascular Disease
Phosphate Lowering in CKD Trial
The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries in adults with moderate to…
- Trial name
- NCT02209636
- Testing
- Lanthanum carbonate, Ascorbic Acid, Nitroglycerin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Diseases
everlinQ Endovascular Access System Enhancements (EASE) Study
Prospective, single-center study to evaluate the everlinQ System when used to create an endoAVF in hemodialysis patients.
- Trial name
- NCT03708770
- Testing
- everlinQ endoAVF System
- Volunteers
- 32 people
- Sponsor
- C. R. Bard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.